Wuyi Focuses On Producing Prescription Drugs For China
This article was originally published in PharmAsia News
China's Wuyi International Pharmaceutical has set a goal of producing a new drug a year as it increases the pharmaceutical portion of its drug business, currently 64 percent. The firm has been around for more than a century, but until its Fujian Sanai subsidiary was established in 2000 and a drug manufacturing license acquired the following year, Wuyi had been producing traditional Chinese medicines. Chairman Lin Ou Wen said the company intends to continue its focus on selling its prescription drugs only to hospitals and clinics, unlike other makers who focus more on over-the-counter products. Lin said prescription drugs are more stable. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.